Mutual of America Capital Management LLC Sells 1,946 Shares of Bruker Corporation $BRKR

Mutual of America Capital Management LLC lessened its stake in shares of Bruker Corporation (NASDAQ:BRKR) by 3.4% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 55,011 shares of the medical research company’s stock after selling 1,946 shares during the period. Mutual of America Capital Management LLC’s holdings in Bruker were worth $2,266,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the business. Stanley Laman Group Ltd. boosted its holdings in shares of Bruker by 13.9% in the 2nd quarter. Stanley Laman Group Ltd. now owns 99,890 shares of the medical research company’s stock valued at $4,115,000 after purchasing an additional 12,154 shares in the last quarter. VELA Investment Management LLC boosted its holdings in shares of Bruker by 80.0% in the 2nd quarter. VELA Investment Management LLC now owns 123,591 shares of the medical research company’s stock valued at $5,092,000 after purchasing an additional 54,928 shares in the last quarter. Bayforest Capital Ltd boosted its holdings in shares of Bruker by 118.7% in the 2nd quarter. Bayforest Capital Ltd now owns 3,075 shares of the medical research company’s stock valued at $127,000 after purchasing an additional 1,669 shares in the last quarter. NorthRock Partners LLC boosted its holdings in shares of Bruker by 21.8% in the 2nd quarter. NorthRock Partners LLC now owns 7,213 shares of the medical research company’s stock valued at $297,000 after purchasing an additional 1,291 shares in the last quarter. Finally, Sequoia Financial Advisors LLC boosted its holdings in shares of Bruker by 15.4% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 33,013 shares of the medical research company’s stock valued at $1,360,000 after purchasing an additional 4,404 shares in the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

Bruker Trading Down 1.8%

NASDAQ:BRKR opened at $39.00 on Friday. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.61 and a quick ratio of 0.70. Bruker Corporation has a 1 year low of $28.53 and a 1 year high of $64.64. The company has a market cap of $5.92 billion, a P/E ratio of 75.00, a P/E/G ratio of 5.49 and a beta of 1.20. The stock’s fifty day moving average price is $34.07 and its two-hundred day moving average price is $37.04.

Bruker (NASDAQ:BRKR) last released its earnings results on Monday, August 4th. The medical research company reported $0.32 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.01). Bruker had a net margin of 2.31% and a return on equity of 17.89%. The firm had revenue of $797.40 million during the quarter, compared to the consensus estimate of $811.17 million. During the same period in the prior year, the company earned $0.52 EPS. The firm’s revenue was down .4% compared to the same quarter last year. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. As a group, analysts expect that Bruker Corporation will post 2.69 EPS for the current year.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, October 3rd. Shareholders of record on Tuesday, September 23rd were issued a $0.05 dividend. The ex-dividend date was Tuesday, September 23rd. This represents a $0.20 annualized dividend and a yield of 0.5%. Bruker’s dividend payout ratio (DPR) is 38.46%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on BRKR shares. Stifel Nicolaus set a $40.00 price objective on Bruker and gave the company a “hold” rating in a report on Tuesday, August 5th. Jefferies Financial Group set a $60.00 price objective on Bruker and gave the company a “buy” rating in a report on Monday, August 4th. Wells Fargo & Company cut their price objective on Bruker from $60.00 to $50.00 and set an “overweight” rating on the stock in a report on Tuesday, August 5th. Weiss Ratings reissued a “sell (d+)” rating on shares of Bruker in a report on Friday. Finally, Citigroup cut their price objective on Bruker from $40.00 to $38.00 and set a “neutral” rating on the stock in a report on Monday, August 4th. Five analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $51.00.

Insider Buying and Selling

In other news, Director Cynthia M. Friend sold 3,535 shares of Bruker stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $32.25, for a total transaction of $114,003.75. Following the completion of the transaction, the director directly owned 18,016 shares in the company, valued at approximately $581,016. This trade represents a 16.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 27.30% of the stock is owned by company insiders.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.